Recent progress toward the clinical development of new anti-MRSA antibiotics

IDrugs

Volumn 6, Issue 4, 2003, Pages 351-359

  Long, Timothy E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

lactam antibiotics; Anti MRSA antibiotics; Cephalosporins; Glycopeptides; Oxazolidinones; Quinolones

Indexed keywords

6 (1 HYDROXYETHYL) 4 METHYL 3 [5 (4 METHYLAMINOMETHYLPHENYL) 3 PYRROLIDINYLTHIO] 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; 7BETA [2 (5 AMINO 1,2,4 THIADIAZOL 3 YL) 2 ETHOXYIMINOACETAMIDO] 3 [(1 METHYLAMINOPROPYL 1H IMIDAZO[4,5 B]PYRIDINIUM 4 YL)METHYL] 3 CEPHEM 4 CARBOXYLIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BAL 2057; BETA LACTAM ANTIBIOTIC; BMS 247243; CAB 175; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN DERIVATIVE; COUMARIN; CP 5068; CP 5609; CP 6679; CS 023; DALBAVANCIN; DAPTOMYCIN; DEPSIPEPTIDE; DK 570K; FANDOFLOXACIN; GARENOXACIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; KATANOSIN B; LIPOPEPTIDE; MC 04546; NB 2001; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; POSIZOLID; QUINOLONE DERIVATIVE; RAMOPLANIN; RU 79115; T 3912; TEICOPLANIN; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VRC 3783; VRC 4104; WAP 8294A 2;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; HUMAN; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

4-QUINOLONES; ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; COUMARINS; HUMANS; METHICILLIN RESISTANCE; OXAZOLES; PEPTIDES; STAPHYLOCOCCUS AUREUS;

EID: 0038030592     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Garrett L: The coming plague. In: The Revenge of the Germs or Just Keep Inventing New Drugs. Penguin Books, New York, NY, USA (1994):411-456. Researchers from the New York City Health Department used polymerase chain reaction genetic fingerprinting to determine that all MRSA bacteria descended from a strain that first emerged in Cairo, Egypt, in 1961.
2. Busk K: The impact of β-lactamases on the development of novel antimicrobial agents. Curr Opin Invest Drugs (2002) 3:1284-1290.
3. Berger-Bächi B, Rohrer B: Factors influencing methicillin resistance in staphylococci. Arch Microbiol (2002) 178:165-171.
4. Di Modugno E, Felici A: The renewed challenge of β-lactams to overcome bacterial resistance. Curr Opin Anti-Infective Invest Drugs (1999) 1:26-39.
5. Lee VJ, Hecker SJ: Antibiotic resistance versus small molecules, the chemical evolution. Med Res Rev (1999) 19:521-542. Review article citing multiple reports on lipophilic cephalosporins and carbapenems with enhanced PBP2a binding capabilities.
6. Glinka TW: Novel cephalosporins for the treatment of MRSA infections. Curr Opin Invest Drugs (2002) 3:206-217. An in-depth report of anti-MRSA cephalosporins in clinical development.
7. Johnson AP, Warner M, Carter M, Livermore DM: In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant Gram-positive cocci. Antimicrob Agents Chemother (2002) 46:321-326.
8. Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN: In vitro activities of RWJ-54428 (MC-02,479) against multiresistant Gram-positive bacteria. Antimicrob Agents Chemother (2001) 45:1442-1430.
9. Cho A, Glinka TW, Ludwikow M, Fan AT, Wang M, Hecker SJ: New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position. Bioorg Med Chem Lett (2001) 11:137-140.
10. Nguyen T, Liu E, Malouin F, Blais J, Chamberland S: MC-02,479/RWJ-54428: Binding to multiple PBPs may be associated with low frequency of resistance. 38th Intersciences Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (1998):Abs F17.
11. Chamberland S, Chan C, Blais J, Mathias M, Malouin F, Lee VJ: MC-02,479, a new cephalosporin with high affinity for PBP2a and stability to staphylococcal β-lactamases. 37th Intersciences Conference on Antimicrobial Agents and Chemotherapy, Toronton, Canada (1997):Abs F178.
12. Glinka T, Huie K, Cho A, Ludwikow M, Blais J, Griffith D, Hecker S, Dudley M: Relationships between structure, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroarylthio)cephems. Discovery of RWJ-333441 (MC-04,546). Bioorg Med Chem (2003) 11:591-600.
13. Jiraskova N: RWJ-333441 Microcide/RW Johnson. Curr Opin Invest Drugs (2001) 2:209-211.
14. Entenza JM, Hohl P, Heinz-Krauss I, Glauser MP, Moreilon P: BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother (2002) 46:171-177.
15. Hebeisen P, Heinz-Krauss I, Angehrn P, Hohl P, Page MG, Then RL: In vitro and in vivo properties of Ro 63-9141, a novel broad spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother (2001) 45:825-836.
16. Ida T, Tsushima M, Ishii T, Atsumi T, Tamura A: CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J Infect Chemother (2002) 8:138-144.
17. Tsushima M, Iwamatsu K, Umemura E, Kudo T, Sato Y, Shiokawa S, Takizawa H, Kano Y, Kobayashi K, Ida T, Tamura A et al: CP6679, a new injectable cephalosporin. Part 1: Synthesis and structure-activity relationships. Bioorg Med Chem (2000) 8:2781-2789.
18. Yamano Y, Miwa H, Motokawa K, Yoshida T, Shimada J, Kuwahara S: S-3578. A new broad-spectrum cephalosporin: II. In vitro activity against Gram-positive and -negative clinical isolates including methicillin-resistant Staphylococcus aureus (MRSA). 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-371.
19. Fujimura T, Yamano Y, Yoshida I, Yoshida T, Shimada J, Kuwahara S: S-3578, a new broad-spectrum cephalosporin: III. Characterization of antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-372.
20. Miwa H, Tsuji M, Yoshida T, Shimada J, Kuwahara S: S-3578, a new broad-spectrum cephalosporin: IV. Evaluation using experimental infection models with MRSA and/ or Pseudomonas aeruginosa. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-373.
21. Johnson AP: Anti-MRSA cephalosporins Bristol-Myers squibb. Curr Opin Invest Drugs (2001) 2:205-208.
22. D'Andrea SV, Bonner D, Bronson JJ, Clark J, Denbleyker K, Fung-Tome J, Hoeft SE, Hudyma TW, Matiskella JD, Miller RF, Misco PF et al: Synthesis and anti-MRSA activity of novel cephalosporin derivatives. Tetrahedron (2000) 56:5687-5698.
23. Kim OK, Hudyma TW, Matiskella JD, Ueda Y, Bronson JJ, Mansuri MM: Synthesis and structure-activity relationship of C-3 quaternary ammonium cephalosporins exhibiting anti-MRSA activities. Bioorg Med Chem Lett (1997) 7:2753-2758.
24. Kim OK, Ueda Y, Mansuri MM, Russell JW, Bidwell VW: Synthesis and structure-activity relationship of C-3 benzoyloxymethyl cephalosporins exhibiting anti-MRSA activities. Bioorg Med Chem Lett (1997) 7:1945-1950.
25. Fung-Tome J, Minassian B, Pucci M, Gradelski E, Huczko E, Washo T, Bonner DP: Anti-staphylococcal activity of a novel MRSA (methicillin-resistant Staphylococcus aureus) cephem BMS-247243. 40th Intersciences Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000):Abs 1063.
26. Singh J, Kim OK, Kissick TP, Natalie KJ, Zhang B, Crispino GA, Springer DM, Wichtowski JA, Zhang Y, Goodrich J, Ueda Y et al: A practical synthesis of an anti-methicillin resistant Staphylococcus aureus cephalosporin BMS-247243. Org Process Res Dev (2000) 4:488-497.
27. Springer DM, Luh BY, Goodrich JT, Bronson JJ: Anti-MRSA cephems. Part 3: Additional C-7 acid derivatives. Bioorg Med Chem (2003) 11:281-291.
28. Springer DM, Luh BY, Goodrich J, Bronson JJ: Anti-MRSA cephems. Part 2: C-7 Cinnamic acid derivative. Bioorg Med Chem (2003) 11:265-279.
29. Springer DM, Luh BY, Bronson JJ: Anti-MRSA cephems. Part 1: C-3 substituted thiopyridinium derivatives. Bioorg Med Chem Lett (2001) 11:797-801.
30. Cubist Pharmaceuticals Inc: Cubist Pharmaceuticals licenses rights to novel cephalosporin antibiotic from Biochemie; IND candidate demonstrates broad-spectrum coverage including MRSA. Press Release (2002) August 01. http://www.cubist.com/corporate_info/
31. Anti-bacterials. Basilea Pharmaceutica Ltd, Basel, Switzerland. http://www.basileapharma.com/frame/b/bantibact_i.html
32. -1).
33. Smyth TP, O'Donnell M, O'Conner MJ, St Ledger JO: β-Lactamase-dependent prodrugs - Recent developments. Tetrahedron (2002) 56:5699-5707. Review article describing the mechanism and applications of β-lactamase prodrugs.
34. Andreoti D, Biondi S: Overview of recent developments in carbapenem and trinem antibiotics. Curr Opin Anti-Infective Invest Drugs (2002) 2:133-139.
35. Miller RA, Humphrey GR, Lieberman DR, Ceglia SS, Kennedy DJ, Grabowski EJ, Reider PJ: A practical and efficient preparation of the releasable naphtosultam side chain of a novel anti-MRSA carbapenem. J Org Chem (2000) 65:1399-1406.
36. Humphrey GR, Miller RA, Pye PJ, Rossen K, Reamer RA, Maliakai A, Ceglia SS, Grabowski EJJ, Volante RP, Reider PJ: Efficient and practical synthesis of a potent anti-MRSA β-methylcarbapenem containing a releasable side chain. J Am Chem Soc (1999) 121:11261-11266.
37. Ratcliffe RW, Wilkening RR, Wildonger KJ, Waddell ST, Santorelli GM, Parker DL Jr, Morgan JD, Blizzard TA, Hammond ML, Heck JV, Hubert J et al: Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: Discovery of L-786,392. Bioorg Med Chem Lett (1999) 9:679-684.
38. Wilkening RR, Ratcliffe RW, Wildonger KJ, Cama LD, Dykstra KD, DiNinno FP, Blizzard TA, Hammond ML, Heck JV, Dorso KL, St Rose E et al: Synthesis and activity of 2-(sulfonamido)methyl-carbapenem: Discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore. Bioorg Med Chem Lett (1999) 9:673-678.
39. Maragni P, Mattioli M, Pachera R, Perboni A, Tamburini B: Preparation of the key intermediate in the synthesis of GV143253A: The anti-MRSA/E injectable trinem. Org Process Res Dev (2002) 6:597-605.
40. Johnson AP, Warner M, Speller DC: In vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus. J Antimicrob Chemother (1998) 42:643-646.
41. Nada J: THF carbapenems (Wyeth Ayerst). Curr Opin Invest Drugs (2001) 2:1035-1038.
42. Imamura H, Ohtake N, Shimizu A, Jona H, Sato H, Sugimoto Y, Nagano R, Ushijima R, Yamada K, Hashizume T: Structure-activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems. Part I: J-111,347 and related compounds. Bioorg Med Chem Lett (2000) 10:109-113.
43. Imamura H, Ohtake N, Shimizu A, Sato H, Sugimoto Y, Sakuraba S, Kiyonaga H, Suzuki-Sato C, Nakano M, Nagano R, Yamada K et al: Structure-activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems. Part 2: J-111,225, J-114,870, J-114,871 and related compounds. Bioorg Med Chem Lett (2000) 10:115-118.
44. Nagano R, Shibata K, Adachi Y, Imamura H, Hashizume T, Morishima H: In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 44:489-495.
45. Shibata K, Nagano R, Hashizume T, Morishima H: Therapeutic efficacy of J-111,225, a novel trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenem, against experimental murine systemic infections. J Antimicrob Chemother (2000) 45:379-382.
46. Fukuoka T, Koga T, Ishii C, Kitayama A, Namba E, Abe T, Nakagawa M, Matsushita Y, Shibayama T, Hirota T, Ohya S et al: CS-023 (R-115685), a novel parenteral carbapenem: II. In vitro and in vivo activities against methicillin-resistant Staphylococcus aureus. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-366.
47. Tessier PR: Intersciences Conference on Antimicrobial Agents and Chemotherapy - 42nd Meeting: Investigational Drugs. IDrugs (2002) 5:1033-1035.
48. 3H]leucine at low MIC levels.
49. Smith DM, Kazi A, Smith L, Long TE, Heldreth B, Turos E, Dou QP: A novel β-lactam antibiotic activities tumor cell apoptotic program by inducing DNA damage. Mol Pharmacol (2002) 61:1348-1358.
50. Dougherty TJ, Barrett JF: Glycopeptide antibiotics: A historical overview and current perspectives. Curr Opin Anti-Infective Invest Drugs (1999) 1:18-25. Describes the development of second-generation glycopeptides.
51. Cetinkaya Y, Falk P, Mayhall CG: Vancomycin-resistant enterococci. Clin Microbiol Rev (2000) 13:686-707.
52. Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin - United States. MMWR (2002) 51:565-567. www.cdc.gov/mmwr/preview/mmmwrhtml/mm5126a1.htm
53. Malabarba A, Ciabatti R: Glycopeptide derivatives. Curr Med Chem (2001) 8:1759-1773.
54. Barrett JF: Oritavancin (Eli Lilly & Co). Curr Opin Invest Drugs (2001) 2:1039-1044.
55. Katz GW, Seo SM, Aeschilmann JR, Houlihan HH, Mercier RC, Rybak MJ: Comparative efficacy of LY333328 [L] in the therapy of experimental methicillin-resistant Staphylococcus aureus [MRSA] endocarditis in rabbits. 37th Intersciences Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (1997):Abs F11.
56. 14C-Oritavancin. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs A-2193.
57. Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ: Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother (2000) 44:2991-2998.
58. Zhanel GG, Kirkpatrick ID, Hoban DJ, Kabani AM, Karlowsky JA: Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob Agents Chemother (1998) 42:2427-2430.
59. Mercier RC, Houlihan HH, Rybak MJ: Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother (1997) 41:1307-1312.
60. Mercier RC, Stumpo C, Rybak MJ: Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother (2002) 50:19-24.
61. Intermune Pharmaceuticals Inc: Intermune Pharmaceuticals - Presentation at the JP Morgan H&Q 21st Annual Healthcare Conference. Company Presentation (2003).
62. Steiert M, Schmitz FJ: Dalbavancin (Biosearch Italia/Versicor). Curr Opin Invest Drugs (2002) 3:229-233.
63. Leighton A, Mrosczcak E, White R, Jabes D, Gottlieb AB, Baylor M, Perry M, Henkel T: Dalbavancin: Phase I single and multiple-dose placebo controlled intravenous safety, pharmacokinetic study in healthy volunteers. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs A-951.
64. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F: In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother (1999) 44:179-192.
65. Kenny MT, Brackman MA, Dulworth JK: In vitro activity of the semisynthetic glycopeptide amide MDL 63,246. Antimicrob Agents Chemother (1995) 39:1589-1590.
66. Borgonovi M, Canenaghi LA, Borghi A, Galimberti M, Kaltofen P, Merati R, Coutant JE: Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat. Antimicrob Agents Chemother (1995) 39:2176-2182.
67. Biosearch Italia SpA: Biosearch Italia announces completion of enrollment for phase II study of once-weekly dalbavancin for skin and soft tissue infections. Press Release (2002) May 21. http://www.biosearch.it
68. Parenti F, Ciabatti R, Cavalleri B, Kettenring J: Ramoplanin: A review of its discovery and its chemistry. Drugs Exp Clin Res (1990) 16:451-455. This article provides an overview of the biological activities of ramoplanin.
69. Fuchs PC, Barry AL, Brown SD: In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother (2002) 49:467-470.
70. Susman E: Interscience Conference on Antimicrobial Agents and Chemotherapy - 42nd Meeting. IDrugs (2002) 5:1024-1027.
71. Alborn WE, Allen NE, Preston DA: Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother (1991) 35:2282-2287.
72. Silverman JA, Oliver N, Andrew T, Li T: Resistance studies with daptomycin. Antimicrob Agents Chemother (2001) 45:1799-1802.
73. Akins RL, Rybak MJ: Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother (2001) 45:454-459.
74. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother (2000) 44:3447-3450.
75. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2001) 45:845-851.
76. 2, a novel anti-MRSA antibiotic produced by Lysobacter sp. J Am Chem Soc (1997) 119:6680-6681.
77. Kato A, Nakaya S, Kokubo N, Aiba Y, Obashi Y, Hirata H, Fujii K, Harada K: A new anti-MRSA antibiotic complex, WAP-8294A. I. Taxonomy, isolation and biological activities. J Antibiot (Tokyo) (1998) 51:929-935.
78. 3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2001) 45:1823-1827.
79. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM: Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother (1997) 41:2132-2136.
80. Matassova NB, Rodnina MV, Endermann R, Kroll HP, Pleiss U, Wild H, Wintermeyer W: Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA (1999) 5:939-946.
81. McKay J, Garvey R: Oxazolidinones and other antibacterials. IDrugs (2002) 5:1030-1032.
82. Gordeev MF, Luehr GW, Gadwood RC, Scott CR, Hackbarth CJ, Lopez S, Trias J, Friis JM, Williams MG, Hosley JD, Courtney M et al: 4′-Amido phenyloxazolidinone thioamides: Antimicrobial activity and pharmacokinetics in rats. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-1047.
83. Johnson AP: AZD-2563 (AstraZeneca). Curr Opin Investig Drugs (2002) 3:848-852.
84. Johnson AP, Warner M, Livermore DM: In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. J Antimicrob Chemother (2002) 50:89-93.
85. Okamoto R, Sato Y, Hosaka Y, Nakano R, Kaieda S, Inoue M: In vitro activity of AZD2563, the new oxazolidinone, against clinical isolates of Gram-positive cocci, including multi-resistant strains. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-1028.
86. AstraZeneca plc: AstraZeneca R&D pipeline: NCEs 25 July 2002. Company World Wide Website (2002). http://www.astrazeneca.com
87. Adriole VT (Ed): The Quinolones. Academic Press, San Diego, CA, USA (1998). Excellent review of the major families of quinolones, their mechanisms of action and biological activity spectrum.
88. Choi KH, Hong JS, Kim SK, Lee DK, Yoon SJ, Choi EC: In-vitro and in-vivo activities of DW-116, a new fluoroquinolone. J Antimicrob Chemother (1997) 39:509-514.
89. Yoshizumi S, Takahashi Y, Murata M, Domon H, Furuya N, Ishii Y, Matsumoto T, Ohno A, Tateda K, Miyazaki S, Yamaguchi K: The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. J Antimicrob Chemother (2001) 48:137-140.
90. Otani T, Tanaka M, Akasaka T, Kurosaka Y, Hayakawa I, Sato K: DK-507k, a new 8-methoxyquinolone: In vitro and in vivo antibacterial activities. 41st Intersciences Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001):Abs F-547.
91. Low DE, Muller M, Duncan CL, Willey BM, De Azavedo JC, McGeer Kreiswirth BN, Pong-Porter S, Bast DJ: Activity of BMS-284756, a novel des-fluoro(6) quinolone against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Antimicrob Agents Chemother (2002) 46:1119-1121.
92. Weller TM, Andrews JM, Jevons G, Wise R: The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother (2002) 49:177-184.
93. Frechette R: T-3811. Toyama/Bristol-Myers Squibb. Curr Opin Invest Drugs (2001) 2:1706-1711.
94. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, Minami S, Watanabe Y, Narita H: In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother (1999) 43:1077-1084.
95. Yamakawa T, Mitsuyama J, Hayashi K: In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother (2002) 49:455-465.
96. Maxwell A: The interaction between coumarin drugs and DNA gyrase. Mol Microbiol (1993) 9:681-686.
97. Annedi SC, Kotra LP: RU-79115 (Aventis Pharma). Curr Opin Invest Drugs (2001) 2:752-754.
98. Musicki B, Periers A-M, Laurin P, Ferroud D, Benedetti Y, Lachaud S, Chatreaux F, Haesslein J-L, Iltis A, Pierre C, Khider J et al: Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkynoviose: Biological activity of RU79115. Bioorg Med Chem Lett (2000) 10:1695-1699.
99. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT: In vitro and in vivo antibacterial activities of novel a glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother (1999) 43:738-744.